关节腔内注射斯普福明与安慰剂对膝骨关节炎患者股胫关节软骨厚度的影响:FORWARD随机临床试验
FORWARD是一项为期5年、在10个中心开展的多中心随机剂量探索试验,纳入549例有症状的影像学膝骨关节炎患者(Kellgren-Lawrence 2或3级)。与安慰剂相比,100 μg斯普福明每6个月或每12个月给药在2年时使股胫关节软骨总厚度变化有统计学显著改善,但临床重要性不确定;30 μg剂量无显著差异。WOMAC评分无显著差异。
要点
- 100 μg斯普福明每6个月或每12个月给药较安慰剂在2年时显著改善股胫关节软骨总厚度,但临床重要性不确定。
- 30 μg斯普福明每6个月或每12个月给药较安慰剂无统计学显著差异。
- 各剂量组与安慰剂组WOMAC评分变化均无统计学显著差异。
核心结论
- 在有症状的影像学膝骨关节炎参与者中,与安慰剂相比,关节腔内注射100 μg斯普福明每6个月或每12个月在2年后使股胫关节软骨总厚度有统计学显著改善,但临床重要性不确定。
- 与安慰剂相比,30 μg斯普福明每6个月或每12个月无统计学显著差异。
- 反应的持久性也不确定。
研究设计与样本
- FORWARD(FGF-18骨关节炎重复给药随机试验)是一项为期5年、剂量探索、多中心随机临床试验,在10个中心开展。
- 纳入标准为年龄40至85岁、有症状的影像学膝骨关节炎且Kellgren-Lawrence分级为2或3级。
- 入组始于2013年7月,止于2014年5月;末次参与者访视发生于2017年5月8日。
- 参与者随机分配至5组之一:100 μg斯普福明每6个月给药(n=110)或每12个月给药(n=110)、30 μg斯普福明每6个月给药(n=111)或每12个月给药(n=110)、或安慰剂每6个月给药(n=108)。
- 每次治疗包括为期3周的每周注射。
主要发现
- 共549例参与者(中位年龄65.0岁;379例女性[69.0%]),474例(86.3%)完成2年随访。
- 与安慰剂相比,从基线至2年股胫关节软骨总厚度变化:100 μg斯普福明每6个月给药为0.05 mm(95%CI,0.03至0.07 mm);100 μg斯普福明每12个月给药为0.04 mm(95%CI,0.02至0.06 mm);30 μg斯普福明每6个月给药为0.02 mm(95%CI,-0.01至0.04 mm);30 μg斯普福明每12个月给药为0.01 mm(95%CI,-0.01至0.03 mm)。
- 与安慰剂相比,100 μg斯普福明每6个月或每12个月给药、30 μg斯普福明每6个月或每12个月给药在WOMAC总分平均绝对变化上均无统计学显著差异。
- 最常报告的治疗中出现的不良事件为关节痛(安慰剂:n=46[43.0%];100 μg斯普福明每6个月给药:n=45[41.3%];100 μg斯普福明每12个月给药:n=50[45.0%];30 μg斯普福明每6个月给药:n=40[36.0%];30 μg斯普福明每12个月给药:n=48[44.0%])。
关键数值与推荐
- 主要终点为2年时通过定量磁共振成像测量的股胫关节软骨总厚度变化。
- 15个次要终点包括2年时WOMAC总分较基线的变化。
- 主要终点的最小临床重要差异(MCID)未知;对于髋和膝骨关节炎患者的总WOMAC评分,绝对MCID为7 U(95%CI,4至10 U),百分比MCID为14%(95%CI,9%至18%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 主要终点的最小临床重要差异未知。
- 反应的持久性也不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sprifermin is under investigation as a disease-modifying osteoarthritis drug. OBJECTIVE: To evaluate the effects of sprifermin on changes in total femorotibial joint cartilage thickness in the more symptomatic knee of patients with osteoarthritis. DESIGN, SETTING, AND PARTICIPANTS: FORWARD (FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses) was a 5-year, dose-finding, multicenter randomized clinical trial conducted at 10 sites. Eligible participants were aged 40 to 85 years with symptomatic, radiographic knee osteoarthritis and Kellgren-Lawrence grade 2 or 3. Enrollment began in July 2013 and ended in May 2014; the last participant visit occurred on May 8, 2017. The primary outcome at 2 years and a follow-up analysis at 3 years are reported. INTERVENTIONS: Participants were randomized to 1 of 5 groups: intra-articular injections of 100 μg of sprifermin administered every 6 months (n = 110) or every 12 months (n = 110), 30 μg of sprifermin every 6 months (n = 111) or every 12 months (n = 110), or placebo every 6 months (n = 108). Each treatment consisted of weekly injections over 3 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was change in total femorotibial joint cartilage thickness measured by quantitative magnetic resonance imaging at 2 years. The secondary end points (of 15 total) included 2-year change from baseline in total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores. The minimal clinically important difference (MCID) is unknown for the primary outcome; for total WOMAC score in patients with hip and knee osteoarthritis, the absolute MCID is 7 U (95% CI, 4 to 10 U) and the percentage MCID is 14% (95% CI, 9% to 18%). RESULTS: Among 549 participants (median age, 65.0 years; 379 female [69.0%]), 474 (86.3%) completed 2-year follow-up. Compared with placebo, the changes from baseline to 2 years in total femorotibial joint cartilage thickness were 0.05 mm (95% CI, 0.03 to 0.07 mm) for 100 μg of sprifermin administered every 6 months; 0.04 mm (95% CI, 0.02 to 0.06 mm) for 100 μg of sprifermin every 12 months; 0.02 mm (95% CI, -0.01 to 0.04 mm) for 30 μg of sprifermin every 6 months; and 0.01 mm (95% CI, -0.01 to 0.03 mm) for 30 μg of sprifermin every 12 months. Compared with placebo, there were no statistically significant differences in mean absolute change from baseline in total WOMAC scores for 100 μg of sprifermin administered every 6 months or every 12 months, or for 30 μg of sprifermin every 6 months or every 12 months. The most frequently reported treatment-emergent adverse event was arthralgia (placebo: n = 46 [43.0%]; 100 μg of sprifermin administered every 6 months: n = 45 [41.3%]; 100 μg of sprifermin every 12 months: n = 50 [45.0%]; 30 μg of sprifermin every 6 months: n = 40 [36.0%]; and 30 μg of sprifermin every 12 months: n = 48 [44.0%]). CONCLUSIONS AND RELEVANCE: Among participants with symptomatic radiographic knee osteoarthritis, the intra-articular administration of 100 μg of sprifermin every 6 or 12 months vs placebo resulted in an improvement in total femorotibial joint cartilage thickness after 2 years that was statistically significant, but of uncertain clinical importance; there was no significant difference for 30 μg of sprifermin every 6 or 12 months vs placebo. Durability of response also was uncertain. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01919164.
引用
- Hochberg MC, Guermazi A, Guehring H, et al. Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial. JAMA. 2019. PMID: 31593273. doi:10.1001/jama.2019.14735
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。